Dogwood Therapeutics, Inc. 8-K

What Happened On January 20, 2026, Dogwood Therapeutics, Inc. (DWTX) filed a Form 8-K (Item 7.01) to disclose that it posted a shareholder letter on its website providing a corporate update. The shareholder letter is furnished as Exhibit 99.1 to the filing. The report was signed by Angela Walsh, Chief Financial Officer, Corporate Secretary and Treasurer, on January 20, 2026.

Key Details

• Filing date: January 20, 2026 (Form 8-K, Item 7.01 - Regulation FD Disclosure).
• Exhibit furnished: Shareholder letter dated January 20, 2026 (Exhibit 99.1).
• Signature: Angela Walsh, CFO, Corporate Secretary and Treasurer, signed the filing.
• Administrative exhibit: Cover Page Interactive Data File referenced (Inline XBRL, Exhibit 104).

Why It Matters The company officially made a corporate update publicly available and complied with Regulation FD by furnishing the shareholder letter in an 8-K. For investors, the important next step is to read the Exhibit 99.1 shareholder letter for any material information about strategy, operations, timelines, or financial guidance. This 8-K does not itself report earnings, management changes, or financial results — it only indicates the company posted the update and made it part of the public record.